GENinCode plc
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GENI.L research report →
Companywww.genincode.com
GENinCode Plc engages in the development and commercialization of clinical genetic tests to provide predictive analysis of risk to a patient's health based on their genes in the United Kingdom and internationally. Its predictive technology provides patients and physicians with preventative care and treatment strategies. The company's molecular tests combine clinical algorithms and artificial intelligence to provide advanced patient risk assessment to predict disease onset.
- CEO
- Matthew Heaton Walls
- IPO
- 2021
- Employees
- 42
- HQ
- Manchester, GB
Price Chart
Valuation
- Market Cap
- $3.35M
- P/E
- -0.55
- P/S
- 1.15
- P/B
- 1.03
- EV/EBITDA
- -0.23
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 47.01%
- Op Margin
- -195.13%
- Net Margin
- -170.49%
- ROE
- -262.16%
- ROIC
- -176.62%
Growth & Income
- Revenue
- $2.70M · 25.05%
- Net Income
- $-4,434,000 · 36.80%
- EPS
- $-0.03 · 65.44%
- Op Income
- $-5,134,000
- FCF YoY
- 30.78%
Performance & Tape
- 52W High
- $5.50
- 52W Low
- $0.90
- 50D MA
- $1.13
- 200D MA
- $1.96
- Beta
- 0.61
- Avg Volume
- 5.83M
Get TickerSpark's AI analysis on GENI.L
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our GENI.L Coverage
We haven't published any research on GENI.L yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate GENI.L Report →